EA201992003A1 - Применение антител к ctla-4 с повышенной adcc для усиления иммунного ответа на вакцину - Google Patents

Применение антител к ctla-4 с повышенной adcc для усиления иммунного ответа на вакцину

Info

Publication number
EA201992003A1
EA201992003A1 EA201992003A EA201992003A EA201992003A1 EA 201992003 A1 EA201992003 A1 EA 201992003A1 EA 201992003 A EA201992003 A EA 201992003A EA 201992003 A EA201992003 A EA 201992003A EA 201992003 A1 EA201992003 A1 EA 201992003A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ctla
antibodies
vaccine
immune response
strengthening
Prior art date
Application number
EA201992003A
Other languages
English (en)
Inventor
Джон Т. Лоффредо
Кэтрин Е. Льюис
Роберт Ф. Грациано
Алан Дж. Корман
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Priority claimed from PCT/US2018/019868 external-priority patent/WO2018160536A1/en
Publication of EA201992003A1 publication Critical patent/EA201992003A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к способам усиления иммунного ответа на вакцину с применением вариантных форм антител к CTLA-4, обладающих повышенной ADCC-активностью. Вариантные антитела к CTLA-4 для применения в настоящем изобретении включают нефукозилированный ипилимумаб.
EA201992003A 2017-03-08 2018-02-27 Применение антител к ctla-4 с повышенной adcc для усиления иммунного ответа на вакцину EA201992003A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762468527P 2017-03-08 2017-03-08
PCT/US2018/019868 WO2018160536A1 (en) 2017-02-28 2018-02-27 Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine

Publications (1)

Publication Number Publication Date
EA201992003A1 true EA201992003A1 (ru) 2020-06-10

Family

ID=71138833

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992003A EA201992003A1 (ru) 2017-03-08 2018-02-27 Применение антител к ctla-4 с повышенной adcc для усиления иммунного ответа на вакцину

Country Status (1)

Country Link
EA (1) EA201992003A1 (ru)

Similar Documents

Publication Publication Date Title
MX2019009660A (es) Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna.
EA201791093A1 (ru) Антитела к cd47, способы и применение
NZ738008A (en) Tigit-binding agents and uses thereof
NZ741129A (en) Anti-pd1 antibodies and methods of use
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
PH12018501611A1 (en) Antigen binding proteins thant bind pd-l1
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
CR20210097A (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
DK3189073T3 (da) Trophoblast-glycoprotein (5t4, tpbg)-specifikke kimære antigenreceptorer til cancerimmunterapi
WO2018075820A3 (en) Cereblon-based heterodimerizable chimeric antigen receptors
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
EA201992756A3 (ru) Антитела против cd48 и их конъюгаты
PH12016501366A1 (en) Novel anti-baff antibodies
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
MX2023006415A (es) Anticuerpos, usos y metodos.